Effect of Add-on Aliskiren to Type 1 Angiotensin Receptor Blocker Therapy on Endothelial Function and Autonomic Nervous System in Hypertensive Patients With Ischemic Heart Disease

Atsuko Ozeki; Eisuke Amiya; Masafumi Watanabe; Yumiko Hosoya; Munenori Takata; Aya Watanabe; Shuichi Kawarasaki; Tomoko Nakao; Shogo Watanabe; Kazuko Omori; Namie Yamada; Yukiko Tahara; Yasunobu Hirata; Ryozo Nagai

doi:10.1111/jch.12366

Effect of Add-on Aliskiren to Type 1 Angiotensin Receptor Blocker Therapy on Endothelial Function and Autonomic Nervous System in Hypertensive Patients With Ischemic Heart Disease

Atsuko Ozeki, Eisuke Amiya, Masafumi Watanabe, Yumiko Hosoya, Munenori Takata, Aya Watanabe, Shuichi Kawarasaki, Tomoko Nakao, Shogo Watanabe, Kazuko Omori, Namie Yamada, Yukiko Tahara, Yasunobu Hirata, Ryozo Nagai

HOSP - University Hospital (not affiliated with any section)

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

The aim of this study was to evaluate the add-on effect of aliskiren to valsartan on endothelial-dependent vasodilation in hypertensive patients with ischemic heart disease (IHD). After 4 weeks of treatment with 80 mg of valsartan, 28 patients were allocated to either continued treatment with valsartan or an add-on treatment with valsartan plus 150 mg of aliskiren. Aliskiren significantly decreased plasma renin activity, whereas endothelium-dependent vasodilation measured by flow-mediated dilation (FMD) did not change. In contrast, heart rate significantly decreased (73.1 ± 9.8 to 66.3 ± 7.0 beats per minute at baseline and 24 weeks, respectively [P = .009]) and the standard deviation of the R-R intervals (SDNN) significantly increased in the aliskiren group. The add-on aliskiren to valsartan therapy may not improve endothelial functions, although it significantly reduced resting heart rate via regulation of the autonomic nervous system in hypertensive patients with IHD.

Original language	English
Pages (from-to)	591-598
Number of pages	8
Journal	Journal of Clinical Hypertension
Volume	16
Issue number	8
DOIs	https://doi.org/10.1111/jch.12366
Publication status	Published - 2014 Aug

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jch.12366

Cite this

Ozeki, A., Amiya, E., Watanabe, M., Hosoya, Y., Takata, M., Watanabe, A., Kawarasaki, S., Nakao, T., Watanabe, S., Omori, K., Yamada, N., Tahara, Y., Hirata, Y., & Nagai, R. (2014). Effect of Add-on Aliskiren to Type 1 Angiotensin Receptor Blocker Therapy on Endothelial Function and Autonomic Nervous System in Hypertensive Patients With Ischemic Heart Disease. Journal of Clinical Hypertension, 16(8), 591-598. https://doi.org/10.1111/jch.12366

@article{9fccae1df4d249aca7a02d1d37085478,

title = "Effect of Add-on Aliskiren to Type 1 Angiotensin Receptor Blocker Therapy on Endothelial Function and Autonomic Nervous System in Hypertensive Patients With Ischemic Heart Disease",

abstract = "The aim of this study was to evaluate the add-on effect of aliskiren to valsartan on endothelial-dependent vasodilation in hypertensive patients with ischemic heart disease (IHD). After 4 weeks of treatment with 80 mg of valsartan, 28 patients were allocated to either continued treatment with valsartan or an add-on treatment with valsartan plus 150 mg of aliskiren. Aliskiren significantly decreased plasma renin activity, whereas endothelium-dependent vasodilation measured by flow-mediated dilation (FMD) did not change. In contrast, heart rate significantly decreased (73.1 ± 9.8 to 66.3 ± 7.0 beats per minute at baseline and 24 weeks, respectively [P = .009]) and the standard deviation of the R-R intervals (SDNN) significantly increased in the aliskiren group. The add-on aliskiren to valsartan therapy may not improve endothelial functions, although it significantly reduced resting heart rate via regulation of the autonomic nervous system in hypertensive patients with IHD.",

author = "Atsuko Ozeki and Eisuke Amiya and Masafumi Watanabe and Yumiko Hosoya and Munenori Takata and Aya Watanabe and Shuichi Kawarasaki and Tomoko Nakao and Shogo Watanabe and Kazuko Omori and Namie Yamada and Yukiko Tahara and Yasunobu Hirata and Ryozo Nagai",

year = "2014",

month = aug,

doi = "10.1111/jch.12366",

language = "English",

volume = "16",

pages = "591--598",

journal = "Journal of Clinical Hypertension",

issn = "1524-6175",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "8",

}

Ozeki, A, Amiya, E, Watanabe, M, Hosoya, Y, Takata, M, Watanabe, A, Kawarasaki, S, Nakao, T, Watanabe, S, Omori, K, Yamada, N, Tahara, Y, Hirata, Y & Nagai, R 2014, 'Effect of Add-on Aliskiren to Type 1 Angiotensin Receptor Blocker Therapy on Endothelial Function and Autonomic Nervous System in Hypertensive Patients With Ischemic Heart Disease', Journal of Clinical Hypertension, vol. 16, no. 8, pp. 591-598. https://doi.org/10.1111/jch.12366

Effect of Add-on Aliskiren to Type 1 Angiotensin Receptor Blocker Therapy on Endothelial Function and Autonomic Nervous System in Hypertensive Patients With Ischemic Heart Disease. / Ozeki, Atsuko; Amiya, Eisuke; Watanabe, Masafumi et al.
In: Journal of Clinical Hypertension, Vol. 16, No. 8, 08.2014, p. 591-598.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Effect of Add-on Aliskiren to Type 1 Angiotensin Receptor Blocker Therapy on Endothelial Function and Autonomic Nervous System in Hypertensive Patients With Ischemic Heart Disease

AU - Ozeki, Atsuko

AU - Amiya, Eisuke

AU - Watanabe, Masafumi

AU - Hosoya, Yumiko

AU - Takata, Munenori

AU - Watanabe, Aya

AU - Kawarasaki, Shuichi

AU - Nakao, Tomoko

AU - Watanabe, Shogo

AU - Omori, Kazuko

AU - Yamada, Namie

AU - Tahara, Yukiko

AU - Hirata, Yasunobu

AU - Nagai, Ryozo

PY - 2014/8

Y1 - 2014/8

N2 - The aim of this study was to evaluate the add-on effect of aliskiren to valsartan on endothelial-dependent vasodilation in hypertensive patients with ischemic heart disease (IHD). After 4 weeks of treatment with 80 mg of valsartan, 28 patients were allocated to either continued treatment with valsartan or an add-on treatment with valsartan plus 150 mg of aliskiren. Aliskiren significantly decreased plasma renin activity, whereas endothelium-dependent vasodilation measured by flow-mediated dilation (FMD) did not change. In contrast, heart rate significantly decreased (73.1 ± 9.8 to 66.3 ± 7.0 beats per minute at baseline and 24 weeks, respectively [P = .009]) and the standard deviation of the R-R intervals (SDNN) significantly increased in the aliskiren group. The add-on aliskiren to valsartan therapy may not improve endothelial functions, although it significantly reduced resting heart rate via regulation of the autonomic nervous system in hypertensive patients with IHD.

AB - The aim of this study was to evaluate the add-on effect of aliskiren to valsartan on endothelial-dependent vasodilation in hypertensive patients with ischemic heart disease (IHD). After 4 weeks of treatment with 80 mg of valsartan, 28 patients were allocated to either continued treatment with valsartan or an add-on treatment with valsartan plus 150 mg of aliskiren. Aliskiren significantly decreased plasma renin activity, whereas endothelium-dependent vasodilation measured by flow-mediated dilation (FMD) did not change. In contrast, heart rate significantly decreased (73.1 ± 9.8 to 66.3 ± 7.0 beats per minute at baseline and 24 weeks, respectively [P = .009]) and the standard deviation of the R-R intervals (SDNN) significantly increased in the aliskiren group. The add-on aliskiren to valsartan therapy may not improve endothelial functions, although it significantly reduced resting heart rate via regulation of the autonomic nervous system in hypertensive patients with IHD.

UR - http://www.scopus.com/inward/record.url?scp=84905725459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905725459&partnerID=8YFLogxK

U2 - 10.1111/jch.12366

DO - 10.1111/jch.12366

M3 - Article

C2 - 25039889

AN - SCOPUS:84905725459

SN - 1524-6175

VL - 16

SP - 591

EP - 598

JO - Journal of Clinical Hypertension

JF - Journal of Clinical Hypertension

IS - 8

ER -

Effect of Add-on Aliskiren to Type 1 Angiotensin Receptor Blocker Therapy on Endothelial Function and Autonomic Nervous System in Hypertensive Patients With Ischemic Heart Disease

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this